BENGALURU: India s Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild Covid-19, as the country grapples with a shortage of medicines and vaccines needed to effectively tackle a devastating second wave of the pandemic.
The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials, the drugmaker said, adding it was found to be safe and well-tolerated.
The therapy is a cocktail of two monoclonal antibodies, which mimic natural antibodies that the body generates to fight infection. At this juncture, there is a critical need to explore safer and more efficacious treatments to combat Covid, Zydus Cadila s managing director, Sharvil Patel, said in a stock exchange filing.
Dr Reddy said use of antibody cocktail treatment for Covid-19 patients can help them recover from the disease within one week. However, the treatment should be given only in hospital settings.
Gurugram (Haryana) [India], May 26 (ANI): An 84-year-old man from Haryana with multiple co-morbidities was discharged from Medanta hospital after getting the jap of monoclonal antibody cocktail. He has become the first person in India to be administered the COVID drug cocktail, which came into the limelight after it was administered to former US President Donald Trump when he tested positive for the virus last year.
URL copied
Roche s Covid antibody cocktail launched in India for treatment of mild to moderate cases
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.
Roche, Cipla launch antibody cocktail Casirivimab and Imdevimab in India: Know price, function, benefits
The antibody cocktail is targeted at mild-to-moderate coronavirus patients above 12 years of age or older and at least weighing 40 kg. (Photo: India.com)
Updated: May 24, 2021, 05:52 PM IST
Indian Pharma giants Roche India and Cipla limited in a partnership have announced the antibody cocktail Casirivimab and Imdevimab, now available in India.
This intravenous administration of the cocktails (Casirivimab & Imdevimab) 4 syringes (2 of each of 2.5ml) need to be injected simultaneously at 4 points on the abdomen or thigh. One patient requires 1200mg of dosage which is 1200mg will be sold at MRP of Rs 59,750. The multi-dose pack containing 2400mg of the cocktail can treat 2 patients per pack will be sold at the MRP of Rs 1,19,500.